Below you will find pages that utilize the taxonomy term “Healthcare”
Neural Implants: Where the Technology Actually Stands Right Now
Fewer than 70 people worldwide have used a brain-computer interface that reads and decodes their neural signals. That number, drawn from the GAO’s April 2026 horizon report, is a useful corrective to the hype cycle that has surrounded this technology for years. The commercial narrative has run far ahead of clinical reality.
The more mature category of neural implants — devices that send electrical signals into the brain to alter its activity — has a larger user base. More than 200,000 people have received deep brain stimulation devices for conditions like Parkinson’s disease and epilepsy. But these are strictly therapeutic, tightly regulated, and available only to patients who have not responded to other treatments. They are not precursors to consumer products. They are medical devices.
Tempus AI and Daiichi Sankyo Bet on Multimodal AI to Sharpen ADC Development
Tempus AI is pushing deeper into drug development partnerships with a new strategic collaboration with Daiichi Sankyo, one centered on a problem that has become increasingly important in oncology: not just building better therapies, but identifying more precisely which patients are most likely to benefit from them. The agreement focuses on accelerating the clinical development and differentiation of an antibody-drug conjugate program by combining Daiichi Sankyo’s clinical trial and preclinical research data with Tempus’ real-world oncology data and AI models.
Thesis Care Rebrands and Raises $45 Million to Expand AI-Powered Clinical Teams
Thesis Care, the healthcare AI company formerly known as Trovo Health, has announced a $45 million Series A round led by Oak HC/FT, with participation from CRV, Black Opal Ventures, and healthcare technology angel investors. The new financing brings the company’s total funding to $60 million and arrives alongside a rebrand that signals a broader push into scalable clinical operations for healthcare organizations. The timing feels deliberate, almost like a reset moment as the company moves from early validation into something closer to full-scale deployment.